Blog – Page 3 – Biocortech S.A.S.

NEWS & EVENTS

Biocortech and Drug Safety Executive Council announce Technology Evaluation Consortium to validate novel toxicogenomic screening assay to predict potential drug-induced psychiatric adverse events Announcement Paris Biopark, Paris, France and Drug Safety Executive Council (DSEC), Needham, Massachusetts, United States- June 17, 2010 – Biocortech, the biopharmaceutical company dedicated to the development of drug safety screening assays and…

CUSTOMERS & PARTNERS

Biocortech is very much partner-oriented and relationships with our customers and partners are key to the development of Biocortech’s technology and services. Over years, Biocortech build a network of academic collaborations and industry agreements that cover the different areas of research and development, such as neuronal plasticity. Biocortech acquired a deep understanding of the needs…

PRODUCTS & SERVICES

DIADEP Diagnostic and/or predictive biological test of depression and/or of depression severity (i.e., risk of suicidal behavior) First clinical trial started early 2009. This pilot trial aims at achieving a proof of concept of the test among a sub-population of patients EDITOX Drug screening assay of predictive neuropsychiatric toxicology of new chemical entities EDITOX® is…

SCIENCE & TECHNOLOGY

Receptor editing – which was initially described in immunology – is a regulation mechanism of key receptors (e.g. 5HT2cR, AMPAR) involved in brain diseases (such as depression, schizophrenia or neurodegenerative diseases) or in the mechanism of action of pharmacological agents (such as an antidepressant or anti-obesity drugs). Biocortech has developed the only technology enabling a…

BOARD OF DIRECTORS

Dinah Weissmann Chairman of the Board, Chief Executive Director Jean François Pujol Director, Chief Scientific Director Jean Paul Leon Director Previously CFO and Executive VP Corporate Strategy of Sanofi. Jean-Paul is an expert of the big pharma environment. As a previous member of Sanofi top management, he was a strong contributor for more 25 years…

Management Team

Dinah Weissmann has served as Biocortech Chief Executive Officer since the founding of the company in 2001. Dr Weissmann is an expert in neurobiology, with 20 years’ experience in R&D; management. Prior to founding Biocortech, Dinah was a Senior Scientist at Roussel Uclaf (now Sanofi-Aventis). Her research background includes an appointment as a Research Director at…

Business strategy

Diagnostics Biocortech is completing clinical proof of concept of its in vitro diagnostics tests for disease management of brain disorders and is interested in collaborating on their regulatory development, industrialization, marketing and commercialization, with industry partner(s) having a franchise in in vitro diagnostic market. Biocortech contemplates possibilities to develop and commercialize diagnostic tests for niche…

Home

Biocortech is focusing on developing diagnostic application of receptor editing, an emerging field of rapidly growing interest that the company pioneered for the last years. Biocortech is now addressing the emerging market of biological testing of neuropsychiatric diseases and aiming at being an early entrant in the market of biological testing of depression, with a proprietary…